Valeant Pharmaceuticals International, Inc. raised bidding price from $6.50 to $7.50 per share in cash relevant to its earlier proposed price for the acquisition of ISTA Pharmaceuticals. This proposal according to Valeant will be closed by the end of current month.

Moreover, Valeant showed a will to reach at a price of about $8.50 per share for selected confirmatory due diligence associated with the ISTA that shows consistency with the expectation of Valeant.

Board of Directors of ISTA Pharmaceuticals, Inc. allowed a shareholder rights plan which permits all equity owners of January 27, 2012 will be given rights to buy among preferred stock. Recent rights plan is the replacement for the company’s previous rights plan that expired on January 12, 2012.

Both Valeant Pharmaceuticals and ISTA Pharmaceuticals as the name describes belongs to healthcare sector which ended positive with a net change of 0.66% after last trading session.

Valeant Pharmaceuticals Int (USA) (NYSE:VRX) commenced last trading with a price of $50.31 and rallied up to $51.11 during the day but finished the trade at $50.98 with a gain of 3.64%.

VRX traded with a volume of 5.77 million shares, higher from average volume of 1.95 million shares. The week-performance of the company after last close appeared at +3.98%, 1 year performance moved at +45.53%, and year-to-date performance appeared positive with +9.19% while a month-performance after last trade went up +17.11%.

The liquidity measure in recent quarter results of the company was recorded 1.27 as current ratio and on the other side the debt to equity ratio was -1.30 while long-term debt to equity ratio remained -1.29. VRX had a cash of $13.08 per share and a book value per share as $0.86 in the most recent quarter.

ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA) started last trading at an opening price of $8.08 and during the session hit at $8.26 but when closing bell rang the stock finally advanced 13.07% to $8.22.

The liquidity measure in recent quarter results of the company was recorded -0.94 as current ratio. ISTA had a cash of $1.25 per share and a book value per share as -$0.83 in the most recent quarter.

Shares price of ISTA is ahead its 52 week low with 185.42% and logging behind from its 52 week high price with -27.83%. ISTA stock price volatility for a week moved about 1.83%. In share capital ISTA has 41.50 million outstanding shares among them 40.50 million shares have been floated in market exchange. ISTA stock institutional ownership remained 78.53% while insider ownership included 2.55%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.